Plaintiff May Amend Warning, Fraud Claims in Truvada Action, Hawaii Federal Judge Rules



DOCUMENTS
  • Order


HONOLULU — A Hawaii federal judge has allowed the plaintiff in a case targeting Gilead Sciences Inc.’s HIV drug Truvada to replead his failure-to-warn claims, finding they are not preempted by federal law because the drug maker could have changed the label via the FDA’s Changes Being Effected process.

In an Aug. 31 order, Judge Derrick K. Watson of the U.S. District Court for the District of Hawaii further ruled that the plaintiff may amend his fraud and breach of warranty claims. However, the judge held that the design defect claims are preempted because Gilead could not unilaterally change the …

FIRM NAMES
  • Lyons Brandt Cook & Hiramatsu
  • Sidley Austin LLP





UPCOMING CONFERENCES




HarrisMartin's Webinar Series: The Paragard IUD Litigation

November 10, 2020 - Haddonfield, NJ
HarrisMartin Webinar Series

MORE DETAILS



HarrisMartin's Webinar Series: TDF HIV Litigation

November 11, 2020 - Haddonfield, NJ
HarrisMartin Webinar Series

MORE DETAILS